1 completed, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow VIT-2763: new trials by email Literature Review of VIT-2763 trials Research Report on VIT-2763
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg - Sickle Cell Disease | Phase 2 | Completed | Vifor (International) Inc. | 25 | 2021-11-18 | 2025-02-18 |
| Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID - Beta-Thalassemia | Phase 2 | Withdrawn | Vifor (International) Inc. | 2021-09-20 | 2022-11-10 |
Anemia (1) · Anemia, Sickle Cell (1) · beta-Thalassemia (1)
Vifor (International) Inc. (2)
United States (2) · Bulgaria (1) · France (1) · Greece (1) · Israel (1) · Lebanon (1) · United Kingdom (1)